AstraZeneca And Daiichi Sankyo Pull Dato-DXd File in EU On Heels Of US Switch

 
• By Kevin Grogan

The partners have decided to voluntarily withdraw their EU marketing application for datopotamab deruxtecan in lung cancer, based on regulator feedback, a month after a similar move in the US.

Futuristic medical concept with blue human lungs
AstraZeneca used a proprietary AI-based model to analyze TROP2 expression • Source: Shutterstock

More from Immuno-oncology

More from Business